# Expanded Access to Bezuclastinib to be Coadministered With Sunitinib for Patients With Gastrointestinal Stromal Tumors

> clinical trial · VERIFIED · 2026-07-13

Status: AVAILABLE · Sponsor: Cogent Biosciences, Inc. · Condition: Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors

- Company: Cogent Biosciences, Inc.
- Sector: Gastrointestinal Neoplasms, Gastrointestinal Stromal Tumors
- Primary source: https://clinicaltrials.gov/study/NCT06948955

---
Source: MedFuel Intel news monitor. Verification tier: VERIFIED. Informational only, not investment advice. Corrections: media@medfuelinc.com.